PT840607E - Nova utilizacao medica - Google Patents
Nova utilizacao medicaInfo
- Publication number
- PT840607E PT840607E PT96918965T PT96918965T PT840607E PT 840607 E PT840607 E PT 840607E PT 96918965 T PT96918965 T PT 96918965T PT 96918965 T PT96918965 T PT 96918965T PT 840607 E PT840607 E PT 840607E
- Authority
- PT
- Portugal
- Prior art keywords
- pct
- medical use
- new medical
- sec
- date
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502219A SE9502219D0 (sv) | 1995-06-19 | 1995-06-19 | Novel medical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT840607E true PT840607E (pt) | 2002-09-30 |
Family
ID=20398663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96918965T PT840607E (pt) | 1995-06-19 | 1996-06-10 | Nova utilizacao medica |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6096772A (pt) |
| EP (1) | EP0840607B1 (pt) |
| JP (1) | JPH11507921A (pt) |
| KR (1) | KR19990023021A (pt) |
| CN (1) | CN1091595C (pt) |
| AT (1) | ATE214925T1 (pt) |
| AU (1) | AU706660B2 (pt) |
| BR (1) | BR9608472A (pt) |
| CA (1) | CA2225175A1 (pt) |
| CZ (1) | CZ289400B6 (pt) |
| DE (1) | DE69620186T2 (pt) |
| DK (1) | DK0840607T3 (pt) |
| EE (1) | EE03385B1 (pt) |
| ES (1) | ES2173294T3 (pt) |
| HK (1) | HK1010152A1 (pt) |
| HU (1) | HUP9901448A3 (pt) |
| IL (1) | IL122659A (pt) |
| IS (1) | IS4619A (pt) |
| MY (1) | MY114716A (pt) |
| NO (1) | NO975922L (pt) |
| NZ (1) | NZ310606A (pt) |
| PT (1) | PT840607E (pt) |
| RU (1) | RU2209064C2 (pt) |
| SE (1) | SE9502219D0 (pt) |
| SK (1) | SK172197A3 (pt) |
| UA (1) | UA55387C2 (pt) |
| WO (1) | WO1997000070A1 (pt) |
| ZA (1) | ZA964690B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| SE9800550D0 (sv) * | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| BR0102252B1 (pt) * | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
| WO2003035039A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| WO2004066997A2 (en) * | 2003-01-30 | 2004-08-12 | Lek Pharmaceuticals D.D. | Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods |
| PL1750862T3 (pl) | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
| US8979838B2 (en) | 2010-05-24 | 2015-03-17 | Arthrocare Corporation | Symmetric switching electrode method and related system |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| GB2263637A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists |
| GB2263638A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists |
| GB2263639A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| GB2263635A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
| US5250558A (en) * | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
| DE4203872A1 (de) * | 1992-02-11 | 1993-08-12 | Thomae Gmbh Dr K | Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5212195A (en) * | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
| US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
-
1995
- 1995-06-19 SE SE9502219A patent/SE9502219D0/xx unknown
-
1996
- 1996-06-05 ZA ZA964690A patent/ZA964690B/xx unknown
- 1996-06-10 BR BR9608472A patent/BR9608472A/pt not_active Application Discontinuation
- 1996-06-10 CN CN96196137A patent/CN1091595C/zh not_active Expired - Fee Related
- 1996-06-10 ES ES96918965T patent/ES2173294T3/es not_active Expired - Lifetime
- 1996-06-10 RU RU98101105/14A patent/RU2209064C2/ru not_active IP Right Cessation
- 1996-06-10 KR KR1019970709491A patent/KR19990023021A/ko not_active Application Discontinuation
- 1996-06-10 EE EE9700366A patent/EE03385B1/xx not_active IP Right Cessation
- 1996-06-10 AU AU11840/97A patent/AU706660B2/en not_active Ceased
- 1996-06-10 DK DK96918965T patent/DK0840607T3/da active
- 1996-06-10 US US08/702,522 patent/US6096772A/en not_active Expired - Fee Related
- 1996-06-10 SK SK1721-97A patent/SK172197A3/sk unknown
- 1996-06-10 IL IL12265996A patent/IL122659A/xx not_active IP Right Cessation
- 1996-06-10 CZ CZ19973730A patent/CZ289400B6/cs not_active IP Right Cessation
- 1996-06-10 NZ NZ310606A patent/NZ310606A/en unknown
- 1996-06-10 PT PT96918965T patent/PT840607E/pt unknown
- 1996-06-10 EP EP96918965A patent/EP0840607B1/en not_active Expired - Lifetime
- 1996-06-10 WO PCT/SE1996/000758 patent/WO1997000070A1/en not_active Application Discontinuation
- 1996-06-10 DE DE69620186T patent/DE69620186T2/de not_active Expired - Fee Related
- 1996-06-10 AT AT96918965T patent/ATE214925T1/de not_active IP Right Cessation
- 1996-06-10 JP JP9502982A patent/JPH11507921A/ja active Pending
- 1996-06-10 CA CA002225175A patent/CA2225175A1/en not_active Abandoned
- 1996-06-10 HU HU9901448A patent/HUP9901448A3/hu unknown
- 1996-06-19 MY MYPI96002480A patent/MY114716A/en unknown
- 1996-10-06 UA UA97126085A patent/UA55387C2/uk unknown
-
1997
- 1997-11-25 IS IS4619A patent/IS4619A/is unknown
- 1997-12-16 NO NO975922A patent/NO975922L/no not_active Application Discontinuation
-
1998
- 1998-10-14 HK HK98111234A patent/HK1010152A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9603228D0 (en) | Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies | |
| SE9500422D0 (sv) | New oral pharmaceutical dosage forms | |
| IL114446A (en) | Pharmaceutical preparation for pain management and process for its preparation | |
| PT758241E (pt) | Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses | |
| IL127044A0 (en) | Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases | |
| PT840607E (pt) | Nova utilizacao medica | |
| HK1014870A1 (en) | Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms | |
| SE9402880D0 (sv) | New peptide derivatives | |
| SE9501881D0 (sv) | New pharmacological use of AII-receptor antagonists | |
| SE9504267D0 (sv) | New therapeutic use | |
| HUT70521A (en) | Process to prepare pharmaceutical comps. again amyloidosis | |
| ATE155683T1 (de) | Arzneimittel zur verhinderung der toleranzentwicklung während der behandlung mit benzodiazepin-rezeptor-bindenden wirkstoffen | |
| FR2762214B1 (fr) | Utilisation de la mizolastine pour la preparation d'un medicament destine au traitement de l'inflammation |